newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Seeking Alpha
Immix rises after mid-stage trial data for AL amyloidosis therapy.
Immix Biopharma announced mid-stage trial data for NXC-201 in AL amyloidosis.
KEY POINTS
NXC-201 is being tested for a rare disease involving abnormal light chain accumulation.
Following the announcement, Immix Biopharma's stock price rose.
Specific details of the mid-stage trial data were not disclosed in the announcement.
Immix rises after mid-stage trial data for AL amyloidosis therapy
May 21, 2026, 7:02 AM ETImmix Biopharma, Inc. (IMMX) StockBy : Dulan Lokuwithana, SA News Editor
Comment
(1)
Immix Biopharma (IMMX) traded higher after announcing data from a mid-stage trial for its lead asset, NXC-201, in AL amyloidosis, a rare disease characterized by the accumulation of abnormal light chains in various organs of the body.
The company said
Newsletters for Every Investor
Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters